A breakthrough CRISPR trial brings light to those living in darkness, restoring vision in patients with a rare genetic condition. For Olivia Cook, a 22-year-old college student at Missouri State University, the world had always been a blur, confined to the narrow tunnel of her limited central vision. Born with Leber congenital amaurosis (LCA), Cook experienced life as if peering through a pinhole. However, her visual reality began to change dramatically following her participation in a groundbreaking clinical trial that employed CRISPR, a cutting-edge gene-editing technology, to treat her inherited retinal disorder. The phase 1/2 clinical trial, spearheaded by a collaboration of leading U.S. institutions including Mass Eye and Ear, Perelman School of Medicine at the University of Pennsylvania, and others, aimed to correct mutations responsible for inherited retinal degenerations—a leading cause of blindness globally. The trial marked a significant milestone as it was the first to use t...
As tech enthusiasts and content creators, we produce in-depth reviews of technology products and services and analyze software updates, market trends, and shift-share breakdowns within the tech, film, television and gaming industries, and sports entertainment.